When Merck and Schering-Plough delayed results of a clinical trial aimed at showing the benefits of Vytorin, a top cholesterol drug, they said more time was needed to ensure the validity of the data.
But for years, cardiologists questioned the study, wondering if it could ever prove the drug worked as marketed. Does the drug reduce heart attacks as the companies say it does? Maybe, experts say. The study just may not be able to prove it.
Link to Article
Forbes.com
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
Pharmaceutical News RSS
|
Saturday, December 22
Merck And Schering's Problem Study
by
Alex Hsieh on behalf of Professor Henry Wang
on Sat 22 Dec 2007 11:36 PM EST
Takeda, Astellas Fall After Report of Drug-Price Cuts in Japan
by
Alex Hsieh on behalf of Professor Henry Wang
on Sat 22 Dec 2007 11:34 PM EST
Dec. 17 (Bloomberg) -- Takeda Pharmaceutical Co. and Astellas Pharma Inc., Japan's largest drugmakers, fell in Tokyo trading on a newspaper report that the health ministry will cut subsidies on prescription medicines.
Link to Article Bloomberg.com |
Search
Links
|
||